The impact of Medis QFR® on clinical decision-making
7 mins – November 30, 2023
In his presentation at TCT 2023, Dr. Kobayashi unveiled the transformative potential of Quantitative Flow Ratio (QFR) in reshaping clinical practices within the Cath Lab. This article explores the central themes discussed by Dr. Kobayashi, highlighting key cases that demonstrate how QFR can revolutionize decision-making processes in interventional cardiology.
Understanding QFR Technology
Dr. Kobayashi initiated the presentation by providing a glimpse into the mechanics of QFR technology. He emphasized the simplicity of the process, requiring two orthogonal views of the angiogram. Through automated detection and analysis, the software generates a 3D dimensional model, culminating in a QFR value calibrated against Fractional Flow Reserve (FFR).
Case 1: QFR vs. RFR in Real-Time Decision-Making
The first case presented involved a 70-year-old patient with a history of LAD STEMI. Dr. Kobayashi showcased the real-time decision-making capabilities of QFR, comparing its efficiency against Resting Full-cycle Ratio (RFR). The QFR software, being ahead in the assessment, provided a QFR value of 0.82, ultimately streamlining the decision-making process and reducing procedural time.
Case 2: Retrospective QFR Analysis
In the second case, Dr. Kobayashi introduced the concept of retrospective QFR analysis, illustrating its utility in cases where immediate assessment is challenging. He emphasized the flexibility of QFR, enabling clinicians to perform analyses at a more convenient time, thus eliminating the need for physiologic assessment during non-standard hours.
Case 3: QFR in Multivessel Disease Stratification
The third case delved into the complexities of multivessel disease, presenting a scenario where QFR was employed to stratify patients. By retrospectively analyzing the QFR values, clinicians could reclassify patients and make informed decisions about the necessity of intervention. Dr. Kobayashi highlighted the potential of QFR to guide treatment strategies for patients with three-vessel disease, potentially avoiding unnecessary referrals to CABG.
Case 4: QFR in PCI Strategy Planning
The final case emphasized QFR’s role in planning PCI strategies for patients with diffuse LAD disease. The software not only suggested optimal stent lengths but also predicted post-PCI FFR values. This predictive capability showcased the potential of QFR in enhancing pre-procedural planning and optimizing outcomes.
The Future of Cath Lab Flow
Dr. Kobayashi concluded the presentation by envisioning the future of Cath lab flow, outlining a comprehensive approach that incorporates QFR at various stages. He predicted that QFR would likely replace FFR in 80 to 90% of cases, underscoring its robust validation and versatile applications.
The presentation by Dr. Kobayashi at TCT 2023 underscored the revolutionary impact of QFR on Cath lab practices. From real-time decision-making to retrospective analyses and strategic planning, QFR emerged as a versatile tool with the potential to streamline procedures, reduce radiation exposure, and enhance patient outcomes. As the medical community embraces this technology, the landscape of interventional cardiology is poised for a significant paradigm shift.
Share this article on: